Company Overview and News

Off-market trade in Boon Koon shares at steep discount

KUALA LUMPUR: A total of 25.04 million shares of Boon Koon Group Bhd was traded in an off-market deal at an average price of 33.5 sen on Monday. Stock market data showed the transactions of the company – which manufactures rebuilt and reconditioned vehicles --were at a steep discount to Friday's closing price of 50 sen. Based on its paid-up, the 25.04 million shares accounted for a 8.73% stake.  The shares match the number of shares held by Datin Lee Teoh Kee.

The many changes in Boon Koon

THE changes taking place in Boon Koon Group Bhd are drastic. It is to the extent that minority shareholders who put their money in the company for the automotive business should re-look at their options.

KLCI to expected to advance in line with global gains

2016-12-13 theedgemarkets
KUALA LUMPUR (Dec 14): The FBM KLCI is expected to extend its gains today in line with the overnight gains at most global markets, and on year-end window dressing activities.

Glomac, PDZ Holdings, Kuantan Flour Mills, IHH Healthcare, Magni-Tech Industries, Boon Koon Group and Axiata Group

2016-12-13 theedgemarkets
KUALA LUMPUR (Dec 13): Based on corporate announcements and news flow today, companies that may be in focus on Wednesday (Dec 14) could include: Glomac Bhd, PDZ Holdings Bhd, Kuantan Flour Mills Bhd, IHH Healthcare Bhd, Magni-Tech Industries Bhd, Boon Koon Group Bhd, Axiata Group Bhd

Accsoft, Boon Koon

2016-12-07 theedgemarkets
KUALA LUMPUR (Dec 7): highlighted two stocks with momentum at Bursa Malaysia's afternoon market close today. Both stocks showed negative momentum.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

13h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

13h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...